Genistein (soy isoflavone) / HH Cancer Research Results

GEN, Genistein (soy isoflavone): Click to Expand ⟱
Features: Estrogen-like activity
Genistein is a naturally occurring isoflavone predominantly found in soy products.
It binds estrogen receptors (with relative preference for ERβ over ERα), inhibits certain tyrosine kinases, and modulates PI3K/AKT, NF-κB, MAPK, and cell-cycle pathways in preclinical cancer models. It is also reported to influence angiogenesis and epigenetic regulation. Oral exposure produces conjugated metabolites (glucuronides/sulfates), and free genistein plasma levels are typically much lower than many in-vitro µM concentrations.
-soy isoflavone
Anticancer effects through several mechanisms:
-Modulation of Hormone Activity: can bind to estrogen receptors(hormone-dependent cancers like breast and prostate cancer).
-Inhibition of Cell Proliferation:- -inducing cell cycle arrest.
-Induction of Apoptosis:- by influencing pro- and anti-apoptotic regulators.
-Anti-inflammatory and Antioxidant Effects:-antioxidant properties help to neutralize ROS
-Anti-angiogenic Activity:may also inhibit tumor angiogenesis

Key Cellular Signaling Pathways Involved
-Estrogen Receptor Signaling: interacting with estrogen receptors (ERα and ERβ)
-PI3K/Akt/mTOR Pathway:inhibits this pro-survival pathway, leading to reduced cell growth
-MAPK/ERK Pathway: can contribute to cell cycle arrest.
-NF-κB Pathway:may downregulate NF-κB, supporting a reduction in tumor-promoting inflammation.
-Wnt/β-catenin Pathway: involved in cell proliferation, differentiation, and oncogenic transformation.

Dosages often ranging from approximately 40 mg to 100 mg per day for potential therapeutic effects. Genistein has limited bioavailability when ingested as part of the diet. Efforts to enhance its absorption include the use of specific formulations, such as those that combine genistein with other compounds or utilize novel delivery systems.

Genistein — a naturally occurring polyphenolic isoflavone and phytoestrogen found predominantly in soybeans and soy-derived foods, usually present in plants as glycosides that are hydrolyzed to the biologically active aglycone. It is formally classified as a dietary isoflavone, selective estrogen-receptor modulator-like phytochemical, and experimental anticancer agent. Standard abbreviations include GEN and G. Genistein preferentially engages estrogen receptor beta at lower concentrations, but can also activate estrogen receptor alpha as exposure increases; therefore, its biological effects are strongly dependent on dose, tissue, receptor expression, hormonal environment, and life stage. It is also widely used experimentally as a protein-tyrosine-kinase inhibitor, although many laboratory kinase effects require concentrations exceeding typical free systemic exposure after oral intake.

Primary mechanisms (ranked):

  1. Context-dependent estrogen-receptor modulation, with relative preference for ERβ but clinically relevant potential for ERα activation at sufficient exposure.
  2. Inhibition of receptor and non-receptor tyrosine-kinase signaling, including EGFR-associated pathways, with downstream suppression of PI3K/AKT/mTOR and MAPK signaling in responsive models.
  3. Cell-cycle checkpoint activation and growth arrest through cyclin/CDK regulation, p21 induction, and frequently G2/M accumulation.
  4. Topoisomerase II interference and DNA-damage signaling at higher concentrations, contributing to checkpoint activation and apoptosis but also creating a potential genotoxicity constraint.
  5. Intrinsic apoptosis through mitochondrial dysfunction, altered BAX/BCL-2 balance, cytochrome-c release, and caspase activation.
  6. Suppression of NF-κB, STAT3, inflammatory mediators, and tumor-supportive survival transcription.
  7. Epigenetic modulation involving DNMTs, HDACs, histone acetylation, and re-expression of selected tumor-suppressor genes.
  8. Suppression of angiogenesis, epithelial–mesenchymal transition, invasion, and cancer-stem-cell phenotypes through VEGF/HIF-1α, MMP, Hedgehog/GLI, Wnt/β-catenin, and related pathways.
  9. Context-dependent redox modulation: antioxidant and cytoprotective effects are common at nutritional or lower exposure, whereas mitochondrial ROS generation and pro-oxidant cytotoxicity can occur at higher experimental concentrations.
  10. Potential chemo- and radiosensitization through survival-signaling suppression, cell-cycle redistribution, DNA-damage interactions, and inhibition of treatment-induced NF-κB activation; evidence remains predominantly preclinical.

Bioavailability / PK relevance: Oral genistein undergoes extensive intestinal and hepatic glucuronidation and sulfation. Circulating total genistein may reach micromolar concentrations after concentrated preparations, but most is conjugated; pharmacologically active free aglycone concentrations are generally substantially lower. Absorption varies with food matrix, glycoside hydrolysis, intestinal microbiota, dose, formulation, and enterohepatic recycling. Nanoparticle, lipid, phospholipid, and other delivery systems can increase experimental exposure but are not established oncology treatments.

In-vitro vs systemic exposure relevance: Many anticancer studies use approximately 10–100 µM genistein, with pronounced apoptosis, topoisomerase inhibition, or G2/M arrest often occurring at 25–100 µM. These concentrations commonly exceed sustained free-genistein exposure achievable through soy foods or conventional oral supplementation. Lower nanomolar-to-low-micromolar concentrations may still modulate estrogen receptors and transcription, meaning hormonal activity may occur at exposures below those required for direct cytotoxicity.

Clinical evidence status: Extensive preclinical evidence; several small phase I–II or presurgical randomized human studies, principally in prostate and bladder cancer, have evaluated tissue biomarkers and short-term safety. Some studies reported modulation of PSA-related, inflammatory, epigenetic, proliferation, or kinase biomarkers, but consistent tumor regression, recurrence reduction, progression-free survival, or overall-survival benefit has not been demonstrated. Genistein is not an established or approved anticancer therapy and should be classified as an investigational preventive or adjunctive agent rather than a cancer treatment. Particular caution is warranted in estrogen-sensitive disease, during endocrine therapy, with concentrated supplements, and where thyroid function or medication absorption is clinically important.

Genistein Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Estrogen receptor signaling ERβ signaling ↑; ERα signaling ↑ or ↔ (dose-dependent) (context-dependent) Estrogen-responsive transcription ↑ (dose-dependent) P, R, G Hormonal and transcriptional modulation Relative ERβ preference is not absolute. ERα activation becomes important with higher concentrations and in ERα-dominant tissues; tumor effects may therefore be antiproliferative, neutral, or proliferative depending on receptor balance and exposure.
2 Protein tyrosine kinase and EGFR signaling Tyrosine phosphorylation ↓; EGFR signaling ↓ (dose-dependent) Growth-factor signaling ↓ (high concentration only) P, R Mitogenic signaling suppression Genistein is commonly used experimentally as a broad tyrosine-kinase inhibitor, but selectivity is limited and many effects occur above nutritional systemic exposure.
3 PI3K AKT mTOR survival axis PI3K ↓; AKT phosphorylation ↓; mTOR signaling ↓ ↔ or ↓ (model-dependent) R, G Reduced survival, growth, and treatment resistance A recurrent downstream mechanism across prostate, breast, bladder, pancreatic, and other experimental cancer systems.
4 Cell-cycle checkpoints p21 ↑; cyclin B1 and CDK1 activity ↓; G2/M arrest ↑ Cell-cycle progression ↓ (high concentration only) G Cytostasis and checkpoint activation G2/M arrest is common, although G0/G1 or S-phase effects occur depending on cell type, exposure, and concurrent DNA damage.
5 Topoisomerase II and DNA damage Topoisomerase II function ↓; DNA strand breaks ↑; checkpoint signaling ↑ (high concentration only) Genotoxic stress ↑ (high concentration only) P, R, G DNA-damage-associated arrest and cell death This mechanism may contribute to anticancer activity but is also a safety constraint because topoisomerase II poisoning can produce chromosomal damage rather than selective tumor toxicity.
6 Mitochondrial apoptosis BAX and BCL-2 ratio ↑; mitochondrial membrane potential ↓; cytochrome c ↑; caspases ↑; apoptosis ↑ Apoptosis ↔ or ↓ at lower exposure; ↑ (high concentration only) R, G Programmed cell death Usually follows suppression of survival signaling, cell-cycle disruption, mitochondrial stress, or DNA damage.
7 NF-κB and inflammatory signaling IKK activity ↓; NF-κB activation ↓; COX-2 ↓; inflammatory cytokines ↓ Inflammatory signaling ↓ R, G Anti-inflammatory and anti-survival transcription May reduce tumor-promoting inflammation and treatment-induced survival signaling without constituting a tumor-selective cytotoxic mechanism.
8 STAT3 signaling STAT3 phosphorylation ↓; survivin ↓; BCL-2 ↓ ↔ or ↓ (model-dependent) R, G Reduced survival and stemness Reported particularly in pancreatic, prostate, breast, and other constitutively STAT3-active models.
9 Epigenetic regulation DNMT activity ↓; HDAC activity ↓; histone acetylation ↑; tumor-suppressor expression ↑ Epigenetic transcription ↔ or altered (context-dependent) G Epigenetic reprogramming Effects vary by dose and locus. Human presurgical studies demonstrate gene-expression and methylation changes but do not establish clinical anticancer efficacy.
10 Hedgehog GLI and cancer stemness SMO ↓; GLI1 ↓; CD44 ↓; stemness ↓; EMT ↓ ↔ G Reduced cancer-stem-cell phenotype Supported mainly by cell and xenograft studies using breast and prostate cancer models.
11 Wnt beta-catenin and EMT β-catenin signaling ↓; Snail ↓; Slug ↓; migration ↓; invasion ↓ ↔ or pathway modulation (context-dependent) G Reduced invasive phenotype Not universal across tumor types and frequently secondary to broader kinase, ER, or epigenetic effects.
12 HIF-1α VEGF angiogenesis axis HIF-1α ↓; VEGF ↓; MMP2 and MMP9 ↓; angiogenesis ↓ Angiogenic signaling ↔ or ↓ (model-dependent) G Anti-angiogenic and anti-invasive activity Predominantly demonstrated in preclinical tumor and endothelial models.
13 Mitochondrial ROS modulation ROS ↓ at lower exposure or ROS ↑ at cytotoxic exposure (dose-dependent) (model-dependent) Oxidative stress ↓ commonly; ROS ↑ possible (high concentration only) P, R, G Context-dependent antioxidant or pro-oxidant activity ROS neutralization should not be assigned as a fixed direction. Pro-oxidant mitochondrial stress can participate in apoptosis, while lower exposure commonly activates antioxidant and anti-inflammatory responses.
14 NRF2 antioxidant response NRF2 signaling ↑ or ↓ (context-dependent) NRF2 and antioxidant enzymes ↑ commonly R, G Secondary redox adaptation NRF2 activation may protect normal tissue but could also support tumor stress tolerance in some settings; it is not a consistent primary anticancer mechanism.
15 Chemosensitization Drug response ↑; NF-κB, AKT, STAT3, EMT, and resistance signaling ↓ (model-dependent) Treatment injury ↓ or ↔ (model-dependent) R, G Potential enhancement of cytotoxic therapy Reported with several chemotherapy agents in preclinical models, but sequence, dose, hormonal context, antioxidant effects, and pharmacokinetic interactions can alter the result. Clinical benefit is unproven.
16 Radiosensitization Radiation response ↑; survival signaling ↓; DNA-damage persistence ↑ (model-dependent) Radiation injury ↓ or ↑ (model-dependent) R, G Potential radiation-response modification Predominantly preclinical. Genistein has also shown normal-tissue radioprotective effects in some models, making timing and dose critical.
17 Clinical Translation Constraint Free intracellular exposure often below concentrations used for direct cytotoxicity Hormonal and off-target effects remain possible at lower exposure G Limited translation of laboratory cytotoxicity Extensive glucuronide and sulfate conjugation, variable absorption, ER-dependent bidirectional effects, topoisomerase-related genotoxicity, heterogeneous formulations, small biomarker trials, and absence of demonstrated survival benefit limit oncology use.

P: 0–30 min    R: 30 min–3 hr    G: >3 hr
HH, Hedgehog signaling: Click to Expand ⟱
Source: CGL-CF
Type: HH
Sonic hedgehog, Shh; Indian hedgehog, Ihh; Desert hedgehog, Dhh ; Hh signaling pathway is able to regulate the EMT. Hh signaling-related factors, SHH, SMO and GLI1.
Hedgehog signaling is a crucial pathway in embryonic development and tissue homeostasis, but its dysregulation has been implicated in various cancers. The Hedgehog (Hh) pathway is activated by the binding of Hedgehog ligands (such as Sonic Hedgehog, Indian Hedgehog, and Desert Hedgehog) to their receptors, primarily Patched (PTCH) and Smoothened (SMO).

-Hedgehog pathway is crucial for the maintenance of stem cell populations. When deregulated, it can help sustain cancer stem cells (CSCs) that possess self-renewal properties, drive tumor recurrence, and confer resistance to conventional therapies.

-Inhibitors of the pathway, such as vismodegib and sonidegib, have been developed and are used in clinical settings, particularly for treating advanced BCC and other Hedgehog-dependent tumors.
Scientific Papers found: Click to Expand⟱
28- GEN,    Genistein decreases the breast cancer stem-like cell population through Hedgehog pathway
- in-vivo, BC, MCF7
HH↓, Smo↓, Gli1↓, TumCG↓, TumCP↓, Apoptosis↑, CSCs↓,
166- GEN,  EGCG,  RES,  CUR,    Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer
- in-vivo, Pca, NA
HH↓, Gli1↓,
29- GEN,    Genistein inhibits the stemness properties of prostate cancer cells through targeting Hedgehog-Gli1 pathway
- in-vivo, Pca, 22Rv1 - in-vivo, Pca, DU145
HH↓, Gli1↓, CSCs↓, TumCI↓, EMT↓, TumCG↓, CD44↓,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD44↓, 1,   CSCs↓, 2,   EMT↓, 1,   Gli1↓, 3,   HH↓, 3,   Smo↓, 1,   TumCG↓, 2,  

Migration(tgid=13) ⓘ

TumCI↓, 1,   TumCP↓, 1,  
Total Targets: 10

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: HH, Hedgehog signaling
3 Genistein (soy isoflavone)
1 EGCG (Epigallocatechin Gallate)
1 Resveratrol
1 Curcumin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:85  Target#:141  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page